Date | Title | Description | |
---|---|---|---|
07 Nov 2024 | On P&L | The Company releases the press release related to the first nine months 2024 financial results | Download |
07 Nov 2024 | On P&L | The Company releases the first nine months 2024 financial results presentation | Download |
24 Oct 2024 | On corporate transactions | ROVI completes the strategic review of its CDMO business | Download |
31 Jul 2024 | On P&L | The Company releases the press release related to the first half 2024 financial results | Download |
31 Jul 2024 | On P&L | The Company releases the first half 2024 financial results presentation | Download |
Pages
Date | Title | Description | |
---|---|---|---|
13 May 2020 | Interim Management Report | The company releases the press release related to the 2020 first quarter financial results | Download |
02 Apr 2020 | Liquidity contracts and specialists | Liquidity contract: transactions conducted in the first quarter of 2020 | Download |
02 Apr 2020 | On business and financial situation | ROVI informs on the impact of Covid‑19 on the company’s activities | Download |
26 Feb 2020 | Information on P&L | ROVI releases the press release related to the full year 2019 financial results | Download |
26 Feb 2020 | Information on P&L | ROVI releases the full year 2019 results presentation | Download |
Pages
Date | Title | Description | |
---|---|---|---|
08 Jan 2018 | Contratos de liquidez y contrapartida | Liquidity contract: transactions conducted in the fourth quarter of 2017 | Download |
21 Dec 2017 | Préstamos, créditos y avales | ROVI and the EIB agree to sign a loan to boost research into drug administration and prolonged-release technologies | Download |
08 Nov 2017 | Información sobre Resultados | ROVI releases the press release related to the nine-month period ended 30 September 2017 results | Download |
08 Nov 2017 | Información sobre Resultados | ROVI releases the presentation related to the nine-month period ended 30 September 2017 results. | Download |
24 Oct 2017 | Otros sobre negocio y situación financiera | The Company releases the presentation related to the update of its Phase III-Prima 3 Risperidone ISM® project. | Download |